Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortization of GoodwillAmortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in IntangiblesChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresLong-Term Debt RepaymentsNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based CompensationShares IssuedShort-Term Debt issuances
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Harvard Bioscience (HBIO) Shares Issued (2016 - 2025)

Harvard Bioscience (HBIO) has disclosed Shares Issued for 16 consecutive years, with $46000.0 as the latest value for Q2 2025.

  • On a quarterly basis, Shares Issued fell 75.66% to $46000.0 in Q2 2025 year-over-year; TTM through Sep 2025 was $207000.0, a 51.29% decrease, with the full-year FY2024 number at $380000.0, down 59.14% from a year prior.
  • Shares Issued was $46000.0 for Q2 2025 at Harvard Bioscience, down from $161000.0 in the prior quarter.
  • In the past five years, Shares Issued ranged from a high of $1.9 million in Q1 2021 to a low of $15000.0 in Q1 2024.
  • A 5-year average of $327937.5 and a median of $175000.0 in 2024 define the central range for Shares Issued.
  • Peak YoY movement for Shares Issued: soared 2042.86% in 2021, then crashed 98.39% in 2022.
  • Harvard Bioscience's Shares Issued stood at $405000.0 in 2021, then tumbled by 42.96% to $231000.0 in 2022, then dropped by 10.82% to $206000.0 in 2023, then dropped by 21.84% to $161000.0 in 2024, then crashed by 71.43% to $46000.0 in 2025.
  • Per Business Quant, the three most recent readings for HBIO's Shares Issued are $46000.0 (Q2 2025), $161000.0 (Q4 2024), and $15000.0 (Q3 2024).